Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2014 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2013 Net Income-$371.00K-$371.00KN/M vs Q1 2013 EPS Diluted$0.00$0.00— vs Q1 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Operating Cash Flow-$90,000N/M ended Mar 31, 2014 · filed Jan 8, 2015 · 283 d after period end